DALLAS – May 25, 2007 - Susan G. Komen for the Cure strongly believes that it is past time to make the War on Cancer a priority, increase funds and stimulate a new era of research. Yesterday, the Texas legislature took a broad step in the right direction by passing a bill that would infuse $3 billio

Using MRI may help doctors identify breast cancers missed by mammography in the unaffected breast of newly diagnosed women and in women with a family history and high risk of developing the disease C. Lehman, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast

Breast cancer may have negative impact on long-term quality of life for women over age 70 C. Robb, et al. Impact of breast cancer survivorship on quality of life in older women. Critical Reviews in Oncology/Hematology. April 2007, 62.1: 84-91. E. Perkins, et al. Individual differences in well-bein

Postmenopausal women with ER and PR positive disease could go longer without a recurrence by taking exemestane after five years of tamoxifen therapy, recent study shows E. Mamounas et al. Benefit from exemestane (EXE) as extended adjuvant therapy after five years of tamoxifen (TAM): intent-to-treat

The MammaPrint test will provide information on the likelihood of breast cancer returning within five to ten years after a woman’s initial cancer The United States Food and Drug Administration (FDA) recently cleared for marketing the MammaPrint test, a test that predicts the likelihood of breast ca

Young women use a variety of coping strategies for different stressful aspects of their diagnosis Manuel, Janeen C. et al. Younger Women’s Perceptions of Coping With Breast Cancer. Cancer Nursing. 30(2):85-94, March/April 2007. Young women use a variety of coping strategies to manage different str

Postmenopausal women with ER+, early-stage breast cancer who switch to anastrozole after two to three years of tamoxifen may reduce their risk of dying from breast cancer Boccardo, F. et al. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma. Published online i

The National Comprehensive Cancer Network updates its guidelines for breast cancer risk reduction for women who have not yet had the disease NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. V.I. 2007. National Comprehensive Cancer Network. New guidelines for breast canc

The targeted therapy lapatinib in combination with capecitabine expands treatment options for women with HER2/neu advanced disease whose cancers no longer respond to trastuzumab and other medications The U.S. Food and Drug Administration has approved lapatinib (brand name: Tykerb), a new targeted t

The field of epigenetics may help researchers to develop tests and treatments targeting specific breast cancer types Esteller M. The breast cancer epigenome. Proceedings from the 29th Annual San Antonio Breast Cancer Symposium. Abstract P-1. The study of epigenetics may help researchers develop ne